Meet the Authors

Laura Gately

Senior Vice President, Commercialization

Part 2: Creating Credible Forecasts for Drug Development (Video)

Launching Life Science Brands: A Conversation with Experts on Commercial Readiness

In this video conversation with commercial experts from Herspiegel you’ll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies. 

You will hear from Santosh Naik, a partner here at Herspiegel and leader of Herspiegel Launch Excellence Practice and Laura Gately who is part of the Commercialization Team that works with clients to commercialize life science brands at any point in the product life cycle. 


Market Access Trends for Launch Success

In this report you will find information on external factors and internal capabilities that drive success for Manufacturers launching their products in this challenging Market Access environment.

Part 2: Creating Credible Forecasts for Drug Development


When we think about value, I think of a broader definition. It often starts early in the process with the forecast. What will this brand’s value be at the peak and how will that change over time? So when we think about putting together a realistic and credible forecast, I would advocate that there needs to be a commercial lens on that development. It will have an important impact on your decision-making downstream, driving your company value. Often your brand story is crafted starting at the forecast level. So It should be pressure tested with the commercial viewpoint, or in my opinion, there’s a real risk that key items or assumptions could be missed, which would have a very negative impact downstream. 

Santosh, you worked with several biotech companies for 5-year stretches, what’s been your experience with that?


Yes, it is of critical importance for clinical biotechs to have a credible forecast. Funding and investments are based on having that credible forecast, and clients need a forecast that is both robust and easily able to be refreshed as market dynamics change across the development of the asset. To build a robust credible forecast, primary research with customers is a requirement. Identifying reliable analogs and purchasing additional secondary data sets to supplement your primary research will also help support the generation of that realistic credible forecast. 

Another important development that we have seen through our work with both biotechs and big pharma is the acceleration of market-shaping efforts. Market shaping on branding campaigns typically would be launched 6-12 months before a launch. But we’ve recently seen the trend of unbranded campaigns launching 18 to 24 months before a launch, which forces a firm to start thinking through what their strategic plan would be earlier in the process, as they build out both their branded strategy, but also their unbranded strategy. And that gets back to the original point of beginning planning for your marketing campaigns earlier and earlier in the process.



At Herspiegel we’ve advised over 100 biotech companies in the past 6-7 years, and the majority have relied on external partners to augment their strategic thinking as they prepare for launch. With biotech company budgets and resources being very tight, having the expertise and flexibility and the ability to bounce ideas off those partners, build business cases, and inform decisions with credible benchmarking and best practices across the industry is important. 

At Herspiegel we believe that with a company that is launching their first asset, you have to build the plane as you’re flying it. As part of that, you need to rely on strategic thinking and external partners to support you as you build out a best-in-class strategy. 

If you are a small or a growing biotech company, please reach out and we’d be happy to discuss your situation and how we can help support you to ensure commercial success for your asset.


Market Access Trends for Launch Success

In this report you will find information on external factors and internal capabilities that drive success for Manufacturers launching their products in this challenging Market Access environment:

1. External Factors:

  • Payer trends
  • Competitor trends
  • Policy trends

2. Internal Capabilities:

  • Alignment of internal stakeholders
  • Objective & comprehensive understanding of Market Access environment
  • Understand & prepare for the evolving complexity of stakeholder engagement

"*" indicates required fields

Full Name*

Meet the Authors

Let's Talk

Herspiegel is a leading professional services firm helping biotech start-ups and the world’s largest pharmaceutical companies navigate the path from science to brand performance and change patients’ lives. We are committed to using strategic insights from medical to commercial to market access to solve critical problems.